A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Clinical trial NCT01974440 · COMPLETED
Trial details
- NCT number
- NCT01974440
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-31
- Primary completion
- 2022-05-30
- Enrollment
- 403
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.